No Data
No Data
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $509
Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation
Weekly Buzz: Is Tesla a sign of earnings to come?
Friday Market Falls With Busy Business Ahead | Wall Street Today
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
Mooer's Stories | How Stock_Drift Navigates Irrational Markets